Biosimilar epoetin alpha is as effective as originator epoetin-alpha plus liposomal iron (Sideral (R)), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach

被引：18

作者：

Giordano, Giulio ^{[1
]}

Mondello, Patrizia ^{[3
]}

Tambaro, Rosa ^{[4
]}

Perrotta, Nicola ^{[5
]}

D'Amico, Fabio ^{[8
]}

D'Aveta, Antonietta ^{[1
]}

Berardi, Giuseppe ^{[6
]}

Carabellese, Bruno ^{[2
]}

Patriarca, Andrea ^{[7
]}

Corbi, Grazia Maria ^{[8
]}

Di Marzio, Luigi ^{[2
]}

Licianci, Antonietta ^{[2
]}

Berardi, Donata ^{[9
]}

Di Lullo, Liberato ^{[10
]}

Di Marco, Roberto ^{[8
]}

机构：

[1] Reg Hosp A Cardarelli, Gen Med & Hematol, I-86100 Campobasso, Molise, Italy

[2] Cardarelli Hosp, Serv Dept, I-86100 Campobasso, Molise, Italy

[3] G Martino Univ Hosp, Dept Oncol, I-98100 Messina, Italy

[4] G Pascale Canc Inst, I-80100 Naples, Campania, Italy

[5] Univ G dAnnunzio, Fac Pharmacol, I-66100 Chieti, Italy

[6] Reg Hlth Serv A Cardelli, Family Med, I-86100 Campobasso, Molise, Italy

[7] Publ Hosp, Med & Hematol Unit, I-13900 Biella, Italy

[8] Univ Molise, Sch Med, I-86100 Campobasso, Molise, Italy

[9] Univ Roma La Sapienza, Fac Med, I-00185 Rome, Italy

[10] Reg Hlth Serv A Cardelli, Dept Oncol, I-86100 Campobasso, Molise, Italy

来源：

MOLECULAR AND CLINICAL ONCOLOGY | 2015年 / 3卷 / 04期

关键词：

myelodysplastic syndrome; liposomal iron; hemoglobin; anemia;

D O I：

10.3892/mco.2015.555

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several biosimilar versions of recombinant human erythropoietin are currently approved for use in Europe, including a biosimilar epoetin-alpha. The aim of this the study was to verify that biosimilar epoetin-alpha is similar in terms of efficacy, safety and cost to originator epoetin-alpha for the treatment of refractory anemia in patients with myelodysplastic syndrome. A total of 92 patients with myelodysplasia and refractory anemia were investigated. The patients received either originator (group A) or biosimilar (group B) epoetin-alpha. In addition, they received liposomal iron (Sideral (R)), calcium levofolinate and vitamin B12. Moreover, the median monthly overall costs were calculated for each group. The results demonstrated that hemoglobin (Hb) levels increased by 1 g/dl after a median time of 5 weeks in group A and 4 weeks in group B. In group A, a Hb level of >12 g/dl was achieved after 12 weeks, while in group B after 10.5 weeks. The median cost of therapy was 1,536 euros/month in group A and 1,354 euros/month in group B. A total of 5 patients required transfusion support in group A and 7 in group B. In conclusion, biosimilar epoetin-alpha appears to be comparable to originator epoetin-alpha in terms of efficacy and safety for the treatment of refractory anemia.

引用

页码：781 / 784

页数：4

共 31 条

[11] Myelodysplastic Syndromes
Greenberg, Peter L.
Attar, Eyal
Bennett, John M.
Bloomfield, Clara D.
De Castro, Carlos M.
Deeg, H. Joachim
Foran, James M.
Gaensler, Karin
Garcia-Manero, Guillermo
Gore, Steven D.
Head, David
Komrokji, Rami
Maness, Lori J.
Millenson, Michael
Nimer, Stephen D.
O'Donnell, Margaret R.
Schroeder, Mark A.
Shami, Paul J.
Stone, Richard M.
Thompson, James E.
Westervelt, Peter
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (01): : 30 - 56
[12] Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, Peter L.
Sun, Zhuoxin
Miller, Kenneth B.
Bennett, John M.
Tallman, Martin S.
Dewald, Gordon
Paietta, Elisabeth
van der Jagt, Richard
Houston, Jessie
Thomas, Mary L.
Cella, David
Rowe, Jacob M.
[J]. BLOOD, 2009, 114 (12) : 2393 - 2400
[13] Haag-Weber M, 2009, CLIN NEPHROL, V72, P380
[14] Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:: a randomized multicenter study
Hedenus, M.
Birgegard, G.
Nasman, P.
Ahlberg, L.
Karlsson, T.
Lauri, B.
Lundin, J.
Larfars, G.
Osterborg, A.
[J]. LEUKEMIA, 2007, 21 (04) : 627 - 632
[15] HELLSTROM E, 1991, EUR J HAEMATOL, V47, P355
[16] EFFICACY OF ERYTHROPOIETIN IN THE MYELODYSPLASTIC SYNDROMES - A METAANALYSIS OF 205 PATIENTS FROM 17 STUDIES
HELLSTROMLINDBERG, E
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (01) : 67 - 71
[17] Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy
Henry, David H.
Dahl, Naomi V.
Auerbach, Michael
Tchekmedyian, Simon
Laufman, Leslie R.
[J]. ONCOLOGIST, 2007, 12 (02) : 231 - 242
[18] Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Jädersten, M
Montgomery, SM
Dybedal, I
Porwit-MacDonald, A
Hellström-Lindberg, E
[J]. BLOOD, 2005, 106 (03) : 803 - 811
[19] Mare M, 2011, TUMORI S1, V11, pS118
[20] MORRA E, 1990, EUR J HAEMATOL, V45, P94

← 1 2 3 4 →